Overview

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Status:
Not yet recruiting
Trial end date:
2039-04-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, single-arm clinical study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of CT103A as the first-line treatment in newly diagnosed high-risk multiple myeloma subjects with induction chemotherapy as bridging therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Nanjing IASO Biotherapeutics Co.,Ltd